JP7488534B2 - 新規ながん免疫療法抗体組成物 - Google Patents

新規ながん免疫療法抗体組成物 Download PDF

Info

Publication number
JP7488534B2
JP7488534B2 JP2021509199A JP2021509199A JP7488534B2 JP 7488534 B2 JP7488534 B2 JP 7488534B2 JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021509199 A JP2021509199 A JP 2021509199A JP 7488534 B2 JP7488534 B2 JP 7488534B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
cancer
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021509199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534750A (ja
JP2021534750A5 (https=
JPWO2020038379A5 (https=
Inventor
チャン ジェイ． リ，
シアム ウニラマン，
ハンナ ベイダー，
ミティレシュ ジャ，
Original Assignee
１グローブ バイオメディカル カンパニー， リミテッド
１グローブ ヘルス インスティテュート エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by １グローブ バイオメディカル カンパニー， リミテッド, １グローブ ヘルス インスティテュート エルエルシー filed Critical １グローブ バイオメディカル カンパニー， リミテッド
Publication of JP2021534750A publication Critical patent/JP2021534750A/ja
Publication of JP2021534750A5 publication Critical patent/JP2021534750A5/ja
Publication of JPWO2020038379A5 publication Critical patent/JPWO2020038379A5/ja
Application granted granted Critical
Publication of JP7488534B2 publication Critical patent/JP7488534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021509199A 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物 Active JP7488534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720015P 2018-08-20 2018-08-20
US62/720,015 2018-08-20
PCT/CN2019/101659 WO2020038379A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Publications (4)

Publication Number Publication Date
JP2021534750A JP2021534750A (ja) 2021-12-16
JP2021534750A5 JP2021534750A5 (https=) 2022-08-22
JPWO2020038379A5 JPWO2020038379A5 (https=) 2022-08-22
JP7488534B2 true JP7488534B2 (ja) 2024-05-22

Family

ID=69591356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509199A Active JP7488534B2 (ja) 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物

Country Status (12)

Country Link
US (1) US12391758B2 (https=)
EP (1) EP3841126A4 (https=)
JP (1) JP7488534B2 (https=)
KR (1) KR20210046725A (https=)
CN (2) CN116410320A (https=)
AU (1) AU2019324388A1 (https=)
BR (1) BR112021003182A2 (https=)
CA (1) CA3110138A1 (https=)
MX (1) MX2021002077A (https=)
SG (1) SG11202101757QA (https=)
TW (1) TW202016150A (https=)
WO (1) WO2020038379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187460A1 (en) * 2022-04-01 2023-10-05 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118930652B (zh) * 2024-07-29 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544755A (ja) 2005-07-01 2008-12-11 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
JP2012503984A (ja) 2008-09-26 2012-02-16 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
JP2012511329A (ja) 2008-12-09 2012-05-24 ジェネンテック， インコーポレイテッド 抗ｐｄ−ｌ１抗体およびｔ細胞機能を増強するためのそれらの使用
JP2013511959A (ja) 2009-11-24 2013-04-11 メディミューン リミテッド Ｂ７−ｈ１に対する標的結合剤
JP2015500207A (ja) 2011-11-28 2015-01-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテ 抗ｐｄ−ｌ１抗体及びその使用
JP2015519375A (ja) 2012-05-31 2015-07-09 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−ｌ１に結合する抗原結合蛋白質
JP2016504336A (ja) 2012-12-21 2016-02-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトプログラム死リガンド１（ｐｄ−ｌ１）に結合する抗体
CN106432501A (zh) 2015-08-06 2017-02-22 上海药明生物技术有限公司 新型抗pd‑l1抗体
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2979219A1 (en) 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EA037855B1 (ru) * 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
US12378295B2 (en) * 2018-10-29 2025-08-05 1Globe Biomedical Co., Ltd. Rationally designed protein compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544755A (ja) 2005-07-01 2008-12-11 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
JP2012503984A (ja) 2008-09-26 2012-02-16 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
JP2012511329A (ja) 2008-12-09 2012-05-24 ジェネンテック， インコーポレイテッド 抗ｐｄ−ｌ１抗体およびｔ細胞機能を増強するためのそれらの使用
JP2013511959A (ja) 2009-11-24 2013-04-11 メディミューン リミテッド Ｂ７−ｈ１に対する標的結合剤
JP2015500207A (ja) 2011-11-28 2015-01-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテ 抗ｐｄ−ｌ１抗体及びその使用
JP2015519375A (ja) 2012-05-31 2015-07-09 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−ｌ１に結合する抗原結合蛋白質
JP2016504336A (ja) 2012-12-21 2016-02-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトプログラム死リガンド１（ｐｄ−ｌ１）に結合する抗体
CN106432501A (zh) 2015-08-06 2017-02-22 上海药明生物技术有限公司 新型抗pd‑l1抗体
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3110138A1 (en) 2020-02-27
US20210332138A1 (en) 2021-10-28
JP2021534750A (ja) 2021-12-16
WO2020038379A1 (en) 2020-02-27
EP3841126A4 (en) 2022-08-10
CN112839963B (zh) 2023-02-10
US12391758B2 (en) 2025-08-19
BR112021003182A2 (pt) 2021-05-11
CN116063519A (zh) 2023-05-05
MX2021002077A (es) 2021-05-27
CN116410320A (zh) 2023-07-11
EP3841126A1 (en) 2021-06-30
TW202016150A (zh) 2020-05-01
AU2019324388A1 (en) 2021-03-18
SG11202101757QA (en) 2021-03-30
CN112839963A (zh) 2021-05-25
KR20210046725A (ko) 2021-04-28

Similar Documents

Publication Publication Date Title
JP7790754B2 (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
CN112119097B (zh) 自然杀伤细胞接合抗体融合构建体
CA3051062C (en) Tandem diabody for cd16a-directed nk-cell engagement
CN111094350B (zh) 调节由细胞表达的生物活性的抗体
TWI887193B (zh) 藉由細胞表現之調控生物活性的抗體
JP2024530451A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
TW202221043A (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2023179541A (ja) Ｃｄ３結合分子
JP2024542192A (ja) Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用
JP7488534B2 (ja) 新規ながん免疫療法抗体組成物
EP4480966A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
CN116063519B (zh) 新型癌症免疫治疗抗体组合物
HK40089568A (zh) 新型癌症免疫治疗抗体组合物
HK40089569A (zh) 新型癌症免疫治疗抗体组合物
HK40047112A (en) Novel cancer immunotherapy antibody compositions
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40034204A (en) Nk cell engaging antibody fusion constructs
CN114605546A (zh) Cd3结合分子

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20210419

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240430

R150 Certificate of patent or registration of utility model

Ref document number: 7488534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150